Value-Based Cancer Care Issues


May 2016, Vol 7, No 4

Nivolumab a New Standard-of-Care Option for Recurrent/Metastatic Head and Neck Cancers

Nivolumab a New Standard-of-Care Option for Recurrent/Metastatic Head and Neck Cancers

AACR Meeting Highlights

Anti–PD-1 treatment with the PD-1 inhibitor nivolumab (Opdivo) significantly improved survival in patients with head and neck squamous-cell carcinoma that progressed after platinum-based therapy, according to data from a phase 3 clinical trial known as CheckMate-141. Based on these data, [ Read More ]

FDA News – May 2016

FDA Approvals, News & Updates

Cabometyx Receives FDA Approval for Advanced Renal-Cell Carcinoma On April 25, 2016, the FDA approved cabozantinib (Cabometyx; Exelixis) tablets for the treatment of patients with advanced renal-cell carcinoma (RCC) who had received anti-angiogenic therapy. The FDA granted this approval under [ Read More ]

In the Literature – May 2016

In the Literature

Oncology Benchmarks Annual Report Shows New Patient Visits, Drug Spending Are Rising The oncology National Practice Benchmark (NPB) annual report provides important information regarding oncology providers’ productivity, costs, practice revenues, and profits. Key findings from the 2015 report show that [ Read More ]

Genomic Instability Score Predicts Survival in Patients with Ovarian Cancer

Genomic Instability Score Predicts Survival in Patients with Ovarian Cancer

NCCN Conference Highlights

A higher score on a composite index of homologous recombination deficiency (HRD), indicating genomic instability, correlated with improved progression-free survival (PFS) and overall survival (OS) in patients with ovarian cancer who have received platinum-containing chemotherapy, according to results presented at [ Read More ]